- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-metastatic castration-resistant carcinoma of the prostate Metastatic castration-sensitive carcinoma of the prostate
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 408KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 77KB)
Apalutamide – July 2024
Apalutamide; Tablet 240 mg; Erlyand®
Last updated
30 May 2025